Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning
JAMA · 09.11.2026
DOI: 10.1001/jama.2026.21147 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, online erschienen am 09.11.2026. Verfasst von Hanny Al-Samkari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the new US Food and Drug Administration (FDA) boxed warning for intravenous ferric carboxymaltose, how the warning does not go far enough in explaining the potential dangers, and the risks vs benefits of the drug’s use.
Autor:innen und Institutionen
- Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston.
- Harvard Medical School, Boston, Massachusetts.
- Cure HHT, Monkton, Maryland.
- Georgetown University School of Medicine, Washington, DC.
- Center for Cancer and Blood Disorders, Baltimore, Maryland.
Zitieren
APA
Al-Samkari, H., Olitsky, S., & Auerbach, M. (2026). Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning. JAMA. https://doi.org/10.1001/jama.2026.21147
Vancouver
Al-Samkari H, Olitsky S, Auerbach M. Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning. JAMA. 2026. doi:10.1001/jama.2026.21147
BibTeX
@article{AlSamkari2026,
author = {Al-Samkari, Hanny and Olitsky, Scott and Auerbach, Michael},
title = {Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.21147}
}
EUVIMED